Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | MicrobiomeTrials← Back to trialsNCT06931405
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-05-28Est. Completion: 2026-12-31
Enrollment target: 105 participants Locations- Allervie Clinical Research, Birmingham, Alabama, United States
- Acuro Research, Inc., Little Rock, Arkansas, United States
- Modena Allergy & Asthma Clinical Research - La Jolla, La Jolla, California, United States
- Allergy & Asthma Associates of Southern California, Laguna Niguel, California, United States
- Allergy & Asthma Medical Group and Research Center, San Diego, California, United States
- Allergy Affiliates Inc., Bradenton, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Treasure Valley Medical Research, Boise, Idaho, United States
- Endeavor Health, Northbrook, Illinois, United States
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
- Southern Indiana Clinical Trials, New Albany, Indiana, United States
- The Indiana Clinical Trials Center, Plainfield, Indiana, United States
- Equity Medical - Bowling Green, Bowling Green, Kentucky, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Institute For Asthma & Allergy, Wheaton, Maryland, United States
Other microbiome trials you might be interested in
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on…
North Miami Beach, United StatesEst. completion Aug 23, 2027
Chronic Inducible UrticariaCold UrticariaCold-Induced UrticariaSymptomatic Dermographism
The purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of …
Chesapeake Clinical Research, White Marsh, Maryland, United StatesHenry Ford Health, Detroit, Michigan, United StatesMayo Clinic, Rochester, Minnesota, United StatesThe Clinical Research Center LLC., St Louis, Missouri, United StatesMontana Medical Research, Inc., Missoula, Montana, United StatesEquity Medical (at Cameron Dermatology) - New York, New York, New York, United StatesBernstein Clinical Research Center, Cincinnati, Ohio, United StatesAllergy & Clinical Immunology Associates, Pittsburgh, Pennsylvania, United StatesNational Allergy, Asthma & Urticaria Centers of Charleston, Charleston, South Carolina, United StatesMedical University of South Carolina (MUSC), Charleston, South Carolina, United StatesReveal Research Institute, Dallas, Texas, United StatesAustin Institute for Clinical Research, Pflugerville, Texas, United StatesOdense University Hospital - Odense, Odense, DenmarkFraunhofer-Institut fuer Translationale Medizin und Pharmakologie ITMP - Standort Berlin, Berlin, GermanyUniversitaetsklinikum Carl Gustav Carus Dresden, Dresden, GermanyUniversitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt am Main, GermanyMedizinische Hochschule Hannover (MHH), Hanover, GermanyUniversitaetsmedizin der Johannes Gutenberg - Universitaet Mainz, Mainz, GermanyUniversitaetsklinikum Tuebingen, Tübingen, GermanyAzienda Ospedale - Università Padova, Padova, ItalyAzienda Ospedaliero Universitaria Policlinico Umberto, Rome, ItalyCentro Ricerche Cliniche di Verona s.r.l., Verona, ItalyHospital del Mar, Barcelona, SpainHospital Universitario Vall d'Hebron, Barcelona, SpainHospital Universitari de Bellvitge, Barcelona, SpainHospital Regional Universitario de Malaga, Málaga, SpainNational Taiwan University Hospital Hsin-Chu Branch, Hsinchu, TaiwanKaohsiung Veterans General Hospital (KSVGH), Kaohsiung City, TaiwanTaipei Medical University - Shuang Ho Hospital, New Taipei City, TaiwanChina Medical University Hospital, Taichung, TaiwanNational Taiwan University Hospital, Taipei, TaiwanLinkou Chang Gung Memorial Hospital (CGMHLK), Taoyuan City, TaiwanBirmingham, United StatesEst. completion Jun 2028